FIT Testing update Patricia McLarnon

Slides:



Advertisements
Similar presentations
National Cancer Screening Programmes Bowel Screening Breast Screening Cervical Screening.
Advertisements

Detecting Cancer earlier in Tower Hamlets – The New Network Service Dr. Tania Anastasiadis Tower Hamlets GP Cancer Lead & GP Macmillan facilitator The.
Diabetes Programme Progress Report Dr Charles Gostling, Joint Diabetes Clinical Director October 2013.
Background The 2 week wait referral system was designed to expedite the referral of patients, suspected to have cancer, from Primary to Secondary care.
Achieving improved cancer outcomes- a pathway approach, engaging primary care and partners Kathy Elliott Programme Director – NHS Improving Quality (Delivery.
Version 1 | Internal Use Only© Ipsos MORI 1 Version 1| Internal Use Only Sheffield CCG CCG 360 o stakeholder survey 2014 Summary report.
1 Final Version© Ipsos MORI Final Version Evaluation of Adult Cancer Aftercare Services Quantitative and Qualitative Service Evaluation for NHS Improvement.
Increasing awareness and early diagnosis of cancer An update from Primary Care Jo Preston Service Improvement Facilitator NECN Dr Bill Hall Primary Care.
Commissioner Feedback for SLAM CQC Inspection in September 2015 Engagement with Member Practices 1.
Board Report - Performance September 2008 Produced by Business Intelligence (Performance)
NECN Colorectal NSSG Audit of Waiting Times for Lower GI Cancer Patients in NECN April 2010 – March 2011.
Five Year Forward View: Personal Health Budgets and Integrated Personal Commissioning Jess Harris January 2016.
Improving Cancer Outcomes in Camden Dr Lucia Grun 19 March 2014.
Two-week wait referrals for malignant melanoma: A clinical audit carried out across four UK Cancer Networks South West Cancer Intelligence Service
What data are collected? How, and who by? Karen Graham and Barry Plewa.
ACCESS TO PALLIATIVE CARE FOR UPPER GI CANCER PATIENTS A SURVEY OF 5 CANCER NETWORKS DR Bailey 1 C Wood 2 and M Goodman 3.
TRIAL PARTICIPATION IN THE OVER 60s: A RE-AUDIT OF THE MANAGEMENT OF AML IN THE SOUTH WEST OF ENGLAND South West Cancer Intelligence Service
Baseline The baseline at July Previously there was a lack of consistency for: Pathways into specialist clinics; Policies, procedures and guidelines.
Methods Three questionnaires were designed with reference to national guidelines and the PCRMP’s recommendations. These questionnaires were sent to PCTs,
Asthma - diagnosis and monitoring guideline: primary care implementation feasibility project update Adoption & Impact Programme, NICE: Sally Chisholm,
NBT NEURO-ONCOLOGY PATIENT EXPERIENCE QUESTIONNAIRE 2015 RESULTS SWAG Network Brain and CNS SSG 17 th November 2015 Kings Weston House, Bristol Lois Baldry.
PSA Consensus and The Prostate Cancer Risk Management Programme Karen Stalbow, Prostate Cancer UK Dr Ali Cooper, Prostate Cancer UK Annual Conference 2016.
[NAME CCG] [DATE] [FACILITATOR] Early Diagnosis of Cancer Quality Improvement using Cancer Significant Event Analysis [CCG MAP]
28 Day Faster Diagnosis Standard
FIT Programme (Faecal Immunohistochemical Test)
The capacity challenge:
An Electronic 2 Week Wait Referral System for Colorectal Cancer
Uterovaginal Prolapse
Choice – 6 Steps, 6 Actions, 6 Weeks
Hillingdon CCG CCG 360o stakeholder survey 2014 Summary report.
Uterovaginal Prolapse
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Hernia Local commissioners working with local people for a healthier.
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Knee Replacement Local commissioners working with local people for a.
EFA Briefing for The Trust Network
SWAG Cancer Alliance Update
Recognition and Referral of Suspected cancer NICE NG12 – 2Week Wait
Dr James Carlton, Medical Adviser
HEALTH PROFESSIONAL ENGAGEMENT PROGRAMME:
Multi-Disciplinary Team Meeting Reforms
BOWEL CANCER SCREENING 11/7/18
The School Point of View
National Cancer Diagnosis Audit
Barts Health Trust 2WW Colorectal Workshop Dr Angela Wong,
Guidance on the new Pathway IT System for Mentors
Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance
Multi-Disciplinary Team Meeting Reforms
SW Alliances’ Rapid Diagnostic Pathway for Lung Cancer
West Essex Business Planning Process
Colorectal Cancer Cancer Alliance Work
Faecal Immunochemical Testing (FIT). Update on National Roll Out
Stockport Together Outpatients Business Case Clinical Engagement Event
Commissioner Feedback for SLAM CQC Inspection in September 2015
Two Week Wait Referral Forms
Dry Eyes – Lubricant Eye Drops
NHS Blackburn with Darwen Clinical Commissioning Group
Harrow CCG CCG 360o stakeholder survey 2014 Summary report.
Adherence to Evidence Based Medicine Programme Evidence Summary Pack (Version 2) Correction of Ptosis Local commissioners working with local people for.
The National Cervical Screening Programme
Living With & Beyond Cancer: SWAG Breast SSG Update
FIT for symptomatic patients
What you told us about proposed changes to urgent care in Newcastle
28 Day Faster Diagnosis Standard
Primary Care Commissioning Committee 28th May 2019
NICE has many methods and processes
Living With & Beyond Cancer (Personalised Care): SWAG Colorectal CAG Update 5th June 2019 Catherine Neck, Macmillan Cancer Rehabilitation/ LWBC Lead On.
Direct Access CT Lung Pathway V3 Updated 13/06/2016
NHS Long Term Plan: Rapid Diagnostic Centres (RDC) The SWAG Approach
SWAG Cancer Alliance Rapid Diagnostic Service proposals
NHS DUDLEY CCG Latest survey results August 2018 publication.
Faecal Immunochemistry Test - qFIT
Presentation transcript:

FIT Testing update Patricia McLarnon We cant have the image of the ‘shaking hands’. Not NHE E format

Introduction oduction FIT testing was implemented in primary care across the South West region 2018 - 600 practices FIT was introduced for symptomatic patients who were classed as “low risk, but not no risk” of having colorectal cancer. These are patients who have unexplained symptoms, but did not previously meet the criteria for a suspected cancer referral pathway (amounting to a risk of cancer less than 3%). The first South West evaluation of the data showed, the test has a positive predictive value PPV of 6.2%. This suggests that the risk of cancer in the +ve FIT group is 6.2% -which is more than double the NICE threshold of 3% for a 2ww referral (in NICE NG12). Text

FIT- Results in SWAG SWAG 17% 3761 620 43 24** Locality Positive Rate (average) Tests received (June 2018 to March 2019) Number of Positive tests (June 2018 to March 2019) Number of cancers detected to date (June 2018 to March 2019) No of cancers detected that are stage 1 or 2 SWAG 17% 3761 620 43 24** *Due to waiting times, not all data is available. Incomplete data set from Swindon and no results from North Bristol however, even with incomplete data PPV is still 7% **Not all have staging yet (Glos 7 and Bath may have a few more) Interestingly Gloucester (and North Devon for Peninsula) are identifying a high number of stage 1 – more so that other trusts. We might need to explore this further.

Difference in positivity rates between SWAG and Peninsula The positivity rate in SWAG is consistently higher than in the Peninsula. The reasons for this are not yet known.   Region 2018 2019 Total July–Aug Aug–Sept Sept–Oct Oct-Nov Nov-Dec Dec-Jan Jan-Feb Feb-Mar Mar-April April-May Samples received SWAG 357 375 454 470 509 484 595 517 766 572 5099 Positive 51 58 85 75 91 84 87 89 141 850 % positive 16% 15% 19% 18% 17% Peninsula 325 378 366 374 318 373 508 596 4121 36 38 42 56 48 67 88 551 10% 12% 11% 14% 13%

FIT uptake in SWAG- Uptake of the test is variable across the region CRUK Facilitators CCG % of practices NOT using FIT % of practices who have sent <10 FIT referrals % of practices who have sent >10 FIT referrals BNSSG 2% (2) 29% (24) 69% (58) BaNES 0% (0) 57% (13) 43% (10) Gloucestershire 6% (5) 30% (24) 64% (51) Somerset 22% (15) 57% (38) 21% (14) Wiltshire 6% (3) 31% (15) 63% (30)

Use of FIT testing and Electronic reporting Locality Number of GP practices No samples sent % no samples Electronic reporting % electronic reporting % of those using service BANES   23 0% 16 70% Bristol 42 1 2% 100% Gloucestershire 80 5 6% 7% North Somerset 17 15 88% 94% Somerset 67 14 21% 29 43% 55% South Gloucestershire 25 Wiltshire 48 3 36 75% 80%

GP Education & Experience of FIT To implement the test in primary care an education toolkit was produced including GP guidance (issued May 2018), a website: https://www.nbt.nhs.uk/severn-pathology/pathology-services/clinical-biochemistry/fit-testing and an online video: https://youtu.be/zb1o8ykvS6U This has been distributed to all GPs and practice staff through GP engagement events, via CCGS and additionally, with the kits. To gather detailed feedback from GPs, CR-UK conducted visits to GP Practices across the two alliances and an online survey was conducted the results of which are shown below – 19 responses Emergent trends are being fed back into the programme as targeted improvements. For example safety netting is being improved by supporting the use of read codes for test requests. Questions Yes No I have issued a Faecal Immunochemical Test (FIT) to a patient? 74% 26%   Agree Disagree The guidance I received about the test was sufficient 84% 16% The referral criteria for this test are clear to me 17% 5% I feel confident explaining and issuing this test I am satisfied that I have appropriate safety netting measures in place 63% 37% A negative FIT result will enable me to reassure patients when in the past a referral was needed.

Patient Information and Experience of FIT Patients are provided with information on how to use FIT in the pack they receive from their GP. A survey was included in the pack to ascertain user experience, the results are tabled below. Feedback has been very positive. Patient Survey Results (SWAG only) – 178 Responses About the consultation with your GP   Disagree Agree The GP explained the purpose of the test 10% (15) 90% (134) The GP clearly explained how to use the test 15% (24) 85% (143) The GP clearly explained what would happen when the results come back 16% (28) 84% (137) Using the FIT KIT I understood the test instructions 4% (7) 96% (162) I found it easy to collect my sample 16% (19) 84% (151) I knew what to do with my sample afterwards 3% (5) 97% (162) Further patient information is under development including a video, and leaflet to support GP’s advising patients.

FIT and Secondary Care One of the challenges in launching this test was that there was little supporting data to suggest how it might impact on secondary care. There was concern that it might increase demand on an already constrained service. However, the results of a local audit (Devon) suggested that patients in this cohort were being referred for routine investigations and that the new test should therefore reduce the number of patients undergoing an invasive test unnecessarily. Referral rates into secondary care have been carefully monitored and no notable impact has been seen in the data submissions from providers or raised by clinicians. An in depth audit is being carried out as part of the evaluation programme to understand what happens to FIT negative patients, and when FIT positive patients aren’t referred as well as understand the diagnostic tests this cohort receive. We are now doing a follow up audit to understand what happened to the negative fit patients – did they get referred anyway? How are they managed? Results from this will be available by September. Crucially  through – following feedback through SSG’s, - none of the clinicians have experienced a hike in referral rates due to FIT - that they’ve raised with us.  

Future commissioning of the test Cancer Alliance funding of this test will conclude in March 2020, thereafter it will need to be commissioned by CCG’s. As this is a new test, the project team are embarking on a robust programme of monitoring and evaluation to support commission decision making. This will conclude in January 2021 but an early insights paper will be available in time for the commissioning service planning rounds commencing in September 2019. The evaluation is being commissioned from the DISCOVERY Team, at Exeter University who are assessing the diagnostic performance of the test and health economics. To be robust, the evaluation must include 3500 patients (this is the volume of patients that received a FIT test between July & December 2018). To measure false negatives we need to assess whether any of those 3500 patients went on to develop Cancer within 12 months of their test. This is why the final (publishable) evaluation will not be available until January 2020.

Future commissioning of the test NICE published further guidance in July 2017 (DG30) which encourages the use of the test for any patient with abdominal symptoms who doesn’t fit the NG12 2WW criteria. However, at the moment the Peninsula and SWAG Cancer Alliances are only offering the test to the cohort previously referred to in NG12. The Cancer Alliances will make recommendations on this in its commissioning support paper available for September 2019. Estimated running costs are anticipated to be less than £10 per test total revenue can be estimated from the figures per CCG above.